Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
J ANTIINFECTIVES FOR SYSTEMIC USE
J05 ANTIVIRALS FOR SYSTEMIC USE
J05A DIRECT ACTING ANTIVIRALS
J05AX Other antivirals
J05AX29 Fostemsavir
D10708 Fostemsavir tromethamine (USAN) <US>
USP drug classification [BR:br08302]
Antivirals
Anti-HIV Agents, Other
Fostemsavir
D10708 Fostemsavir tromethamine (USAN)
Drug groups [BR:br08330]
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG01860 Temsavir
D10708 Fostemsavir tromethamine
Transporter substrate
DG01665 ABCB1 substrate
DG01860 Temsavir
D10708 Fostemsavir tromethamine
DG01913 ABCG2 substrate
DG01860 Temsavir
D10708 Fostemsavir tromethamine
Transporter inhibitor
DG02862 ABCG2 inhibitor
DG01860 Temsavir
D10708 Fostemsavir tromethamine
DG02865 SLCO1B1 inhibitor
DG01860 Temsavir
D10708 Fostemsavir tromethamine
DG02907 SLCO1B3 inhibitor
DG01860 Temsavir
D10708 Fostemsavir tromethamine
Antimicrobials [BR:br08307]
Antivirals
Entry, fusion or uncoating inhibitor
HIV gp41/gp120
D10708 Fostemsavir tromethamine (USAN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D10708
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D10708
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D10708
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D10708
Drug transporters
D10708
Drug groups [BR:br08330]
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG01860 Temsavir
Transporter substrate
DG01665 ABCB1 substrate
DG01860 Temsavir
DG01913 ABCG2 substrate
DG01860 Temsavir
Transporter inhibitor
DG02862 ABCG2 inhibitor
DG01860 Temsavir
DG02865 SLCO1B1 inhibitor
DG01860 Temsavir
DG02907 SLCO1B3 inhibitor
DG01860 Temsavir
Prodrugs [br08324.html]
DG01860